Citable company snapshot
Bio-Techne's latest SEC-sourced 2026-03-31 period shows $311.42M in revenue and $51.05M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $311.42M | $295.88M | +5.3% |
| xbrl:GrossProfit | Mar 31, 2026 | $208.29M | $191.28M | +8.9% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $75.50M | $54.46M | +38.6% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $51.05M | $38.01M | +34.3% |
| standalone via YTD differencing | Mar 31, 2026 | $86.66M | $82.41M | +5.2% |
| Free Cash Flow (computed) | Mar 31, 2026 | $77.58M | $76.49M | +1.4% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 6, 2026; accession 0001104659-26-056302.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
